Table 2.

Venetoclax and carfilzomib PK parameters in the plasma

	Cohort 1		Cohort 2		Cohort 3		Cohort 4
	Venetoclax 400 mg+		Venetoclax 800 mg+		Venetoclax 800 mg+		Venetoclax 800 mg+
	carfilzomib 27 mg/m2+		carfilzomib 27 mg/m2+		carfilzomib 70 mg/m2+		carfilzomib 56 mg/m2+
	dexamethasone 40 mg		dexamethasone 40 mg		dexamethasone 40 mg		dexamethasone 40 mg
	C1D1, n = 4	C1D15, n = 4	C1D1, n = 2*	C1D15, n = 3	C1D1, n = 6	C1D15, n = 6	C1D1, n = 3	C1D15, n = 3
Venetoclax PK parameters
Tmax, h†	6.0 (4.0, 8.0)	4.0 (4.0, 6.0)	6.0, 24.0	6.0 (6.0, 8.0)	6.0 (6.0, 6.0)	6.0 (6.0, 8.0)	6.0 (4.0, 6.0)	6.0 (4.0, 6.0)
Cmax, µg/mL	1.57 (1.58, 9)	2.18 (2.47, 57)	0.505, 1.23	2.05 (2.59, 86)	0.915 (1.13, 68)	2.29 (2.69, 51)	1.42 (1.85, 88)	2.85 (2.94, 28)
AUC24, µg × h per mL	19.9 (19.9, 9)	30.2 (33.1, 54)	9.34, 16.7	31.7 (39.9, 86)	14.2 (15.2, 44)‡	33.0 (39.3, 49)	20.8 (24.9, 77)	50.9 (52.5, 30)
Carfilzomib PK parameters	n = 4	n = 3	n = 3	n = 3	n = 5	n = 6	n = 3	n = 3
Tmax, h†	0.58 (0.57, 0.70)	0.57 (0.55, 0.62)	0.58 (0.52, 0.58)	0.67 (0.58, 0.70)	0.55 (0.52, 0.75)	0.55 (0.27, 0.92)	0.52 (0.50, 0.53)	0.50 (0.50, 0.53)
Cmax, ng/mL	135 (384, 87)	501 (574, 67)	351 (368, 34)	455 (483, 42)	519 (661, 62)	852 (982, 50)	263 (377, 95)	429 (600, 97)
AUCinf, ng × h per mL	72.1 (166, 85)	212 (241, 65)	146 (155, 37)	209 (224, 47)	241 (294, 61)	381 (401, 29)	121 (160, 84)	247 (314, 89)
t1/2, h§	0.67 (0.3)	0.75 (0.4)	0.55 (0.1)	0.63 (0.1)	0.58 (0.2)	0.98 (0.3)	0.70 (0.6)	0.83 (0.5)

Data are reported as geometric mean (arithmetic mean, %CV) unless otherwise specified.

AUC₂₄, area under the plasma concentration-time curve over a 24-hour dose interval; AUC_inf, AUC from time 0 to infinity; C1D1: cycle 1, day 1; C1D15: cycle 1, day 15; C_max, maximum observed plasma concentration; CV, coefficient of variation; t_1/2, terminal elimination half-life; T_max, time to C_max.

^*n = 2; presented as individual values.

^†Median (minimum, maximum).

^‡n = 4.

^§Harmonic mean (pseudo standard deviation).